A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

in combination with standard cytarabine/anthracycline induction therapy and cytarabine consolidation therapy for these patients, and as maintenance monotherapy thereafter. Daiichi Sankyo says ...

The results suggest that AZ and Daiichi Sankyo could be in line for ... Gilead is also testing its drug as a first-line therapy for NSCLC in combination with Keytruda in a trial sponsored by ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The FDA bestows a Breakthrough Therapy designation ... QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® (quizartinib) in combination with standard intensive ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

We will now would like to start Daiichi Sankyo's Financial ... started a clinical trial, a phase 3 combination study called TL-12 for adjuvant therapy in non small cell lung cancer, early stage ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer. The FDA has approved ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody ... patients who have tried prior endocrine-based therapy and chemotherapy. The TROP2-directed ADC ...

German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company ... However, classical immune cell engagers, combination therapies, and other ...